Navigation Links
Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results

ic nephropathy and we are

actively pursuing ways to monetize this asset.

-- Extended our research collaboration agreement with Bristol-Myers

Squibb Company to develop and commercialize novel therapies targeted

against the Liver X Receptor. We also received a milestone payment of

$5.0 million from Bristol-Myers Squibb as a result of the acceptance

of an IND, or foreign equivalent.

-- Submitted XL139 to Bristol-Myers Squibb Company in December 2007 under

our oncology collaboration agreement. In January 2008, Bristol-Myers

Squibb exercised its option to develop and commercialize XL139,

thereby triggering a $20.0 million selection milestone payment, and we

exercised our option to co-develop and co-commercialize the compound

in the United States and receive royalties on product sales outside of

the United States.

-- Received $18.0 million from the sale of a major portion of our plant

trait assets to Agrigenetics, Inc., a wholly-owned subsidiary of The

Dow Chemical Company.

-- Sold an 80.1% stake in Artemis to Taconic Farms, for $19.8 million.

Corporate Development

-- Completed a public offering of common stock, raising net proceeds of

$71.9 million.

-- Appointed Richard E. Buller, M.D., Ph.D. to the newly created position

of Vice President, Translational Medicine, Arthur DeCillis, M.D. to

the position of Vice President, Clinical Research, and Anne Champsaur,

M.D. to the position of Vice President, Drug Safety.

-- Appointed Jose Baselga, M.D., a leading expert in oncology drug

discovery, to our Scientific Advisory Board.

-- Appointed Carl B. Feldbaum, president emeritus of the Biotechnology

Industry Organization, to our Board of Directors.

"2007 was an exceptional year in the growth and development of Exelixis -- w

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Exelixis Announces February 14 Webcast of Its Fourth Quarter and Full Year 2007 Financial Results Conference Call
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Exelixis Announces Senior Management Promotions
5. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
6. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
7. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
8. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
11. Exelixis Sells 80% Stake in Artemis to Taconic
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... ... October 08, 2015 , ... Talon Innovations, a provider of ... other technology-driven industries, announces that it is one of three finalists for the Minnesota ... On Thursday, September 25 Talon Innovations was recognized as a nominee for this ...
(Date:10/7/2015)... , October 8, 2015 ... Medical biotechnology accounts for largest bioinformatics ... bioinformatics in drug discovery and development process ... . --> ... On the basis of applications, the bioinformatics ...
(Date:10/7/2015)... Worth, Texas (PRWEB) , ... October 07, 2015 ... ... Cell Institute ( ) will present a public educational seminar on the ... on Saturday, October 10th from 1:00 pm – 3:00 pm at the Hilton ...
Breaking Biology Technology:
... Private Life Science Companies from ... Southern California, ... life science community, is proud to announce that its,second annual BIOCOM ... from Oct. 31-Nov. 2, 2007. Featuring almost 60 innovative public ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... commercializing proprietary product candidates for the treatment,of ... Evan M. Levine,ADVENTRX,s chief executive officer, is ... Annual Growth Conference on Wednesday,September 19th, 2007 ...
... Agreement, COPENHAGEN, September 13 Genmab A/S ... exchange agreement with,Medarex, Inc. Under the terms of ... which targets IL-8, and Medarex will,receive full rights ... will release to each other all previously held ...
Cached Biology Technology:
(Date:10/6/2015)... LAKE CITY , Oct. 6, 2015 ... company, announced today that it has signed a contract ... monitoring services across the full range of sentences under ... Group,s President of the Americas. "This contract with the ... region of the US and advances our position as ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/30/2015)... Sept. 30, 2015  The U.S. Court of Appeals ... key ruling in favor of Crossmatch ™, affirming ... scanner company Suprema and its U.S. partner Mentalix violated ... trade provision that declares it unlawful to engage in ... two of Crossmatch,s patents, the 5,900,993 patent and the ...
Breaking Biology News(10 mins):
... successfully aiding in the replacement of narrowed, calcified ... open-chest surgery. According to a study reported at ... for Cardiovascular Angiography and Interventions (SCAI), May 9?2, ... with the CoreValve Revalving System (CoreValve, Irvine, CA) ...
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... at UNIVET, a spin-off of the Universitat Autònoma de ... Petcare, have developed an artificial cellular model which faithfully ... allow, therefore, the carrying out of various lines of ... need to use live animals. , The basic structure ...
Cached Biology News:
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
... Explorer processes up to 48 lanes, 24 ... input can be from either slab gel ... primer chemistries. The detection parameters in Explorer ... analyst consistency. We have built Explorer ...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Biology Products: